Procaps Group, S.A EBIT 2020-2023 | PROCF
Procaps Group, S.A ebit from 2020 to 2023. Ebit can be defined as earnings before interest and taxes.
Procaps Group, S.A Annual EBIT
(Millions of US $) |
| 2022 |
$40 |
| 2021 |
$70 |
| 2020 |
$63 |
| 2020 |
$-1 |
| 2019 |
$37 |
| 2019 |
$-0 |
| 2018 |
$-0 |
Procaps Group, S.A Quarterly EBIT
(Millions of US $) |
| 2023-09-30 |
$13 |
| 2023-06-30 |
$15 |
| 2023-03-31 |
$3 |
| 2022-12-31 |
$2 |
| 2022-09-30 |
$17 |
| 2022-06-30 |
$18 |
| 2022-03-31 |
$2 |
| 2021-12-31 |
$36 |
| 2021-09-30 |
$18 |
| 2021-06-30 |
$16 |
| 2021-03-31 |
$-0 |
| 2020-12-31 |
$-0 |
| 2020-09-30 |
$14 |
| 2020-06-30 |
$-0 |
| 2020-03-31 |
$-0 |
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
$-0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.125B |
$0.410B |
|
Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps Group, formerly known as Union Acquisition Corp. II, is based in BARRANQUILLA, Colombia.
|
